Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Type: Journal article
Title: Pharmacogenetics of opioid response
Author: Somogyi, A.
Coller, J.
Barratt, D.
Citation: Clinical Pharmacology and Therapeutics, 2015; 97(2):125-127
Publisher: Wiley
Issue Date: 2015
ISSN: 0009-9236
Statement of
AA Somogyi, JK Coller and DT Barratt
Abstract: For opioids requiring CYP2D6 O-demethylation to active metabolites, poor metabolizers have reduced metabolite formation and minimal pain reduction. Clinically, this has only reliably been shown for tramadol. Ultra-rapid metabolizers have an increased risk of toxicity especially for codeine. ABCB1 genetics show no consistent findings. In Asian populations, the high OPRM1 118A>G frequency associates with higher opioid dosage requirements. Clinical translation of opioid genetics is premature because many important pain and addiction phenotype factors contribute.
Keywords: Humans
Cytochrome P-450 Enzyme System
Analgesics, Opioid
Rights: © 2014 American Society for Clinical Pharmacology and Therapeutics
DOI: 10.1002/cpt.23
Published version:
Appears in Collections:Aurora harvest 3
Pharmacology publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.